DHA (cat. no. D7439), CCl₄ (cat. no. 488488) and dimethyl sulfoxide (cat. no. D2650) were purchased from MilliporeSigma. 740Y-P (cat. no. P0175) was purchased from MedChemExpress. Dulbecco's modified Eagle's medium (DMEM; cat. no. 11995-065), fetal bovine serum (FBS), phosphate-buffered saline (PBS), penicillin-streptomycin solution (100X), mitomycin and trypsin EDTA were purchased from Gibco, Thermo Fisher Scientific, Inc. Small interfering RNA (siRNA) targeting VEGFA, VEGFR1 and VEGFR2, and negative control (NC) siRNA were obtained by Nanjing KeyGen Biotech. Co., Ltd. Wild-type (WT) 3′UTR-psiCHECK2-VEGFA and mutant (MUT) 3′UTR-psiCHECK2-VEGFA plasmids were obtained by Hedgehogbio Co., Ltd. P3^*Flag-CMV-14-HSP60 and its NC (empty plasmid) were purchased from Eproll. Co., Ltd. AAV8-GP-3-rno-miR-29b-3p mimic, AAV8-GP-3-rno-miR-29b-3p mimic NC, miR-29b-3p mimic, mir-29b-3p inhibitor and their NC vectors were obtained by Jima Biological Company. The corresponding siRNA and plasmid sequences are listed in Table SI.

The animal experiment was approved by Institutional and Local Committee of Nanjing University of Chinese Medicine (approval no. A20402; Nanjing, China). The present study was carried out based on the guidelines of the Care and Use of Animals of Nanjing University of Chinese Medicine. A total of 36 male Sprague Dawley rats (weight, 220-260 g; age, 6 weeks) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. Rats were maintained under a standard 12-h light/dark cycle, at an indoor temperature of 20±2°C and humidity of 50±10%, and their bedding was autoclaved. Rats received standard food (5 g/100 g/day) and drinking water (11 ml/100 g/day). The health and behavior of the animals were monitored once a day to ensure reliability of the experiments. A liver fibrosis model was constructed via intraperitoneal (IP) injection of CCl₄ and olive oil [1:9 (v/v); 0.5 ml/100 g body weight]. A total of 36 rats were randomly divided into the following six groups (6 rats/group): i) Control group, ii) CCl₄ group, iii) CCl₄ + AAV8-miR NC group, iv) CCl₄ + DHA group, v) CCl₄ + AAV8-miR group and vi) CCl₄ + AAV8-miR + DHA group. The dosage of DHA and administration route were selected based on our previous study (13). CCl₄ and olive oil were injected into rats in all of the groups, with the exception of the control group, every other day from week 1 to week 8. Rats in the control group received olive oil without CCl₄. At the beginning of week 4, rats in the CCl₄ + AAV8-miR NC group were administered AAV8-GP-3-rno-miR-29b-3p mimics NC (6.02×10¹¹ V.G/ml; 32 µl/100 g body weight), whereas rats in the CCl₄ + AAV8-miR and the CCl₄ + AAV8-miR + DHA group were administered AAV8-GP-3-rno-miR-29b-3p mimics (4.16×10¹² V.G/ml; 160 µl/100 g body weight) by caudal vein. At the beginning of week 2, rats in the CCl₄ + DHA group and the CCl₄ + AAV8-miR + DHA group were administered DHA by IP injection (3 mg/ml; 2 g/100 g body weight). DHA was suspended in olive oil and given once a day. The duration of the experiment was 2 months, starting from the first IP injection of CCl₄ until the end of the 8th week. After the experiment, the mice were weighed and were anesthetized with pentobarbital sodium (50 mg/kg). Blood was collected from the orbital vein of rats at a volume of 0.5 ml quickly without delay and immediately underwent biochemical index detection. Subsequently, the rats were euthanized by intraperitoneal injection of an overdose of pentobarbital sodium (100-150 mg/kg). Euthanasia was confirmed through the observation of respiratory, heartbeat, pupil and nerve reflexes, and other indications. Blood and liver samples were collected from rats in each group for serum biochemical analysis, tissue immunofluorescence, reverse transcription-quantitative PCR (RT-qPCR) and western blot analysis.

The rat liver tissues were fixed with 4% paraformaldehyde at 37°C for 0.5 h. The liver tissues were then dehydrated with various concentrations of alcohol, embedded in paraffin and sectioned (5 µm). Subsequently, the sections were stained with hematoxylin (cat. no. BP-DL019; Nanjing SenBeiJia Biological Technology Co., Ltd.) for 5 min, washed with 1X PBS and differentiated with 1% hydrochloric alcohol for a few seconds at room temperature. Finally, the sections were stained with eosin (cat. no. BP-DL010; Nanjing SenBeiJia Biological Technology Co., Ltd.) for 3 min at room temperature. Masson's trichrome and Sirius red staining were used for the evaluation of collagen expression. The Masson's trichrome kit (cat. no. BP-DL371; Nanjing SenBeiJia Biological Technology Co., Ltd) and the Sirius red staining kit (cat. no. BP-DL030; Nanjing SenBeiJia Biological Technology Co., Ltd.) were carried out according to the manufacturer's instructions at room temperature. The representative images were obtained under an inverted light microscope (Zeiss GmbH).

HSCs-LX-2 cells (BNCC337957) were purchased from BeNa Culture Collection; Beijing Beina Chuanglian Institute of Biotechnology. The cells were cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin solution (100X) at 37°C in a humidified incubator with 5% CO₂ and 95% air.

After the HSCs were cultured until they adhered to the wells, DHA was added at 10, 20 and 40 µM for 24 h at 37°C. In addition, cells were treated with 740Y-P (15 µM) for 24 h at 37°C, and with the VEGFR1-specific inhibitor GNQWFI or the VEGFR2-specific inhibitor SU5416 (0.02, 0.2, 2 and 10 µM) for 24 h at 37°C.

According to the instructions, 100 nM siRNA-VEGFA, miR-29b-3p mimic, miR-29b-3p inhibitor, siRNA-VEGFR1 and siRNA-VEGFR2, and 500 ng/µl CMV-14-HSP60, as well as their NCs (with the same concentration) were transfected into LX-2 cells (3×10⁵ cells/well) in 6-well microplates with 3 µl Lipofectamine^® 2000 (cat. no. 11668027; Thermo Fisher Scientific, Inc.). The ratio of plasmid or siRNA with Lipofectamine 2000 was 1:1. The transfected cells were cultured in normal conditions at 37°C for 12 h. RT-qPCR was then performed to verify the transfection efficiency and subsequent experiments were performed. Subsequent experimentation was performed after 12 h of transfection.

The LX-2 cells were lysed with TRIzol^® (Invitrogen; Thermo Fisher Scientific, Inc.), total RNA was collected with isopropanol (Shanghai Aladdin Biochemical Technology Co., Ltd.) and RNA content was determined using an enzyme labeling instrument. In addition, rat liver tissues were cut into pieces and rapidly frozen with liquid nitrogen prior to extraction of total RNA using TRIzol. RNA was then reverse transcribed into cDNA with Hifair^® II 1st Strand cDNA Synthesis kit (Shanghai Yeasen Biotechnology Co., Ltd.) according to the manufacturer's protocol. cDNA was amplified with Hieff Qreal-time PCR SYBR Green main mixture (low Rox +) (Shanghai Yeasen Biotechnology Co., Ltd.) and detected using an Applied Biosystems 7500 system (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. qPCR was performed under the following conditions: Initial denaturation at 95°C for 5 min, followed by 40 cycles at 95°C for 15 sec, 60°C for 60 sec and 72°C for 40 sec, and a final step at 72°C for 5 min. The expression levels of mRNA and miRNA were normalized to β-actin and U6 expression, respectively, and the 2^−ΔΔCq method was used to calculate the expression levels (13). The primer sequences used for RT-qPCR are listed in Table SI.

The LX-2 cells were washed with 1X PBS for three times and then total proteins were extracted using RIPA lysis buffer (cat. no. P0013C; Beyotime Institute of Biotechnology). The rat liver tissues was cut into pieces and rapidly frozen with liquid nitrogen prior to total protein extraction using RIPA lysis buffer. Total protein concentration was determined using the BCA protein analysis kit (cat. no. 23225; Thermo Fisher Scientific, Inc.). The same concentration of proteins (30 µg/sample) were separated by SDS-PAGE and the SDS gel percentage was chosen according to the molecular level of the target protein (10, 12 or 15%). Proteins were then transferred to PVDF membranes (microporous; cat. no. IPVH00010; MilliporeSigma) and blocked with 5% BSA (cat. no. ST025; Beyotime Institute of Biotechnology) at 37°C for 1 h in TBS + 0.1% Tween-20. The PVDF membranes were then incubated with primary antibodies (1:1,000) at 4°C overnight and with the secondary antibody (1:10,000) at 37°C for 2 h. Finally, the membranes were incubated with ECL (cat. no. 32109; Thermo Fisher Scientific, Inc.) and band intensity was semi-quantified by Image Lab software v3.0 (Bio-Rad Laboratories, Inc.). The primary antibodies β-actin (cat. no. AF7018) were purchased from Affinity Biosciences Ltd. The primary antibodies against α-SMA (cat. no. 14395-1-AP), COL1A1 (cat. no. 67288-1-Ig), VEGFA (cat. no. 19003-1-AP) and VEGFR2 (cat. no. 26415-1-AP) were purchased from ProteinTech Group, Inc. The primary antibody against ubiquitin (cat. no. R26024) was purchased from Chengdu Zen Bioscience Co., Ltd. The primary antibodies against VEGFR1 (cat. no. A19132), AKT (cat. no. A20799), phosphorylated (p)-AKT (cat. no. AP1259), mTOR (cat. no. A2445), p-mTOR (cat. no. AP0115), ULK1 (cat. no. A8529), p-ULK1 (cat. no. AP0736), caspase-9 (cat. no. A18676), cytochrome c (cat. no. A4912), AIF (cat. no. A19536), LC3B (cat. no. A19665), Beclin-1 (cat. no. A7353) and P62 (cat. no. A19700) were purchased from ABclonal Biotech Co., Ltd. The HRP Goat Anti-Rabbit IgG (H+L) secondary antibody (cat. no. AS014) and HRP Goat Anti-Mouse IgG (H+L) secondary antibody (cat. no. AS003) were purchased from ABclonal Biotech Co., Ltd.

The protein expression levels of LX-2 cells were measured by immunofluorescence staining. LX-2 cells (1×10⁵ cells/well) were seeded into a 24-well microplate. After intervention, the cells were fixed with 4% paraformaldehyde at 37°C for 0.5 h and blocked with 1% BSA at 37°C for 2 h. The cells were incubated with primary antibodies against α-SMA (cat. no. 14395-1-AP), COL1A1 (cat. no. 67288-1-Ig) and VEGFA (cat. no. 19003-1-AP) (all from ProteinTech Group, Inc.) at 4°C overnight (1:200) and with FITC-conjugated anti-rabbit or anti-mouse secondary antibodies (1:200; cat. nos. ab6717 and ab6785; Abcam) at 37°C for 2 h. All images were captured under an inverted fluorescence microscope (Zeiss GmbH). Liver tissues (5 µm) were also assessed by immunofluorescence staining using the same technique as aforementioned.

LX-2 cells (1×10⁵ cells/well) were seeded into 24-well microplates and stained with 200 µl oil red O (Nanjing Jiancheng Bioengineering Institute) at room temperature for 8 min according to the manufacturer's instructions. The representative images were obtained under an inverted light microscope (Zeiss GmbH).

LX-2 cells (1×10⁵ cells/well) were seeded into 24-well microplates and fixed with 4% paraformaldehyde at 37°C for 0.5 h. Subsequently, they were stained with 500 µl Nile Red (Nanjing Jiancheng Bioengineering Institute) at 37°C for 10 min according to the manufacturer's instructions. The representative images were obtained under an inverted light microscope (Zeiss GmbH).

The TG levels were measured using the TG detection kit (cat. no. SY6206; Yita Biological Co., Ltd.) according to the manufacturer's instructions. After transfection with miR-29b-3p mimic NC, miR-29b-3p mimic, miR-29b-3p inhibitor NC and miR-29b-3p inhibitor, the optical density of cells from the four aforementioned groups was determined at 570 nm using a plate reader (Thermo Fisher Scientific, Inc.).

The total cholesterol (TC) levels were measured using the TC detection kit (cat. no. SY6226; Yita Biological Co., Ltd.) according to the manufacturer's instructions. After transfection with miR-29b-3p mimic NC, miR-29b-3p mimic, miR-29b-3p inhibitor NC and miR-29b-3p inhibitor, the optical density of cells from the four aforementioned groups was determined at 570 nm using a plate reader (Thermo Fisher Scientific, Inc.).

IL-6 levels were measured using an IL-6 ELISA kit (cat. no. RK00004; ABclonal Biotech Co., Ltd.) according to the manufacturer's instructions. LX-2 cells (3×10⁴ cells/well) were seeded into 96-well microplates and incubated at 37°C for 24 h in 5% CO₂. After transfection with VEGFA siRNA, VEGFR1 siRNA and VEGFR2 siRNA, the optical density of the corresponding samples was determined at 570 nm using a plate reader (Thermo Fisher Scientific, Inc.).

LX-2 cells (3×10⁵ cells/well) were seeded into a 6-well microplate. Subsequently, 100 nM miR-29b-3p mimic NC or 100 nM miR-29b-3p mimic was transfected into LX-2 cells, and then 200 ng WT 3′UTR-psiCHECK2-VEGFA vector or MUT 3′UTR-psiCHECK2-VEGFA vector (cat. no. HH-LUC-036, HedgehoBio Science and Technology Co., Ltd.) was transfected into cells with Lipofectamine 2000 at 37°C for 12 h in an atmosphere containing 5% CO₂. Subsequently, cells (1.0×10⁵ cells/ml) were lysed with the lysis buffer in the Luciferase Reporter Gene Assay Kit (cat. no. 11401ES60; Shanghai Yeasen Biotechnology Co., Ltd.), collected and treated with luciferase test reagent (cat. no. 11401-B; Shanghai Yeasen Biotechnology Co., Ltd.). Luciferase activity was measured using a Multiskan FC photometer (Thermo Fisher Scientific, Inc.). Luciferase activity was normalized to a blank control group.

LX-2 cells (1×10⁵ cells/well) were seeded into 24-well microplates and incubated for 24 h at 37°C in 5% CO₂. After intervention, the LX-2 cells were treated with 10 µM JC-1 reagent (cat. no. SY0910; Yita Biological Co., Ltd.) at 37°C for 15 min. Subsequently, JC-1 aggregate fluorescence (excitation wavelength, 530 nm; emission wavelength, 583 nm) and JC-1 monomer fluorescence (excitation wavelength, 488 nm; emission wavelength, 525 nm) were measured using a Multiskan FC photometer (Thermo Fisher Scientific, Inc.). Representative images were captured using an inverted fluorescence microscope (Zeiss GmbH).

Annexin V-FITC/PI double staining assay was conducted with the Annexin V-FITC Apoptosis Detection Kit (Beyotime Institute of Biotechnology). LX-2 cells were collected and dissolved in Annexin V-FITC binding buffer at a density of 1.0×10⁶ cells/ml. Subsequently, 100 µl sample solution was treated with 5 µl FITC-conjugated Annexin V reagent and 5 µl PI reagent, and incubated at room temperature for 15 min in the dark. The percentages of cells within each quadrant (Q1, Q3, Q3 and Q4) were determined using a Gallios flow cytometer (Beckman Coulter, Inc.). The results were analyzed by FlowJo software v10.6.2 (FlowJo, LLC).

LX-2 cells were washed with 1X PBS and total proteins were extracted using 500 µl RIPA lysis buffer (Beyotime Institute of Biotechnology). The homogenates were centrifuged at 1,300 × g for 30 min at 4°C. Subsequently, 20% of the lysate supernatant was used as the input for western blot analysis and the remaining lysate was used to perform the immunoprecipitation assay. The binding/detergent solution (20 mM Na₂HPO₄, 0.15 M NaCl; pH 7.0) was prepared for later use. The HSP60 antibody (cat. no. A0564) was purchased from ABclonal Biotech Co., Ltd.; 5 µl HSP60 antibody was added to the remaining lysate, and the proteins were shaken overnight at 4°C. Subsequently, 50 µl protein A/G plus agarose beads (Santa Cruz Biotechnology, Inc.) were added to the previously prepared antigen-antibody binding complex at 4°C overnight to make them couple with each other. Subsequently, the bead-antibody-antigen complex was centrifuged at 1,300 × g for 3 min at 4°C. The supernatant was carefully extracted, and the agarose beads were washed with 1 ml binding/detergent solution three times. After washing, the magnetic bead-antibody-antigen complex was added to 30 µl 2X SDS-PAGE loading buffer, mixed and heated in a 95°C water bath for 15 min. The supernatant was then taken for western blot analysis.

LX-2 cells (3×10⁴ cells/well) were seeded into 96-well microplates and incubated at 37°C for 24 h in 5% CO₂. After intervention, cells were treated with 10 µl CCK-8 reagent (Shanghai Yeasen Biotechnology Co., Ltd.) and incubated at 37°C for 4 h. The optical density was determined at 570 nm using a plate reader (Thermo Fisher Scientific, Inc.).

LX-2 cells (1×10⁵ cells/well) were seeded into 24-well microplates and incubated at 37°C for 24 h in 5% CO₂. After intervention, the cells were treated with 0.4% trypan blue solution (MilliporeSigma) at a ratio of 9:1 at room temperature for 3 min. The representative images were obtained under an inverted light microscope (Zeiss GmbH).

Rat tail tendon collagen type I (cat. no. C8062; Beijing Solarbio Science & Technology Co., Ltd.) was used to coat a 96-well microplate at the concentration of 2 mg/ml, which was dissolved in 0.006 mol/l acetic acid. NaOH (0.1 mol/l) was then added to promote gelation at 37°C for 2 h. The uncoated well was used as the negative control. Each well was washed three times with 1X PBS, and the LX-2 cells (5×10⁴ cells/well) were seeded into the coated and uncoated wells, before being incubated for 0.5, 1 and 2 h at 37°C in 5% CO₂. Subsequently, each well was washed with 1X PBS to remove the unattached cells. The viability of adherent cells was measured using an MTT assay. Dimethyl sulfoxide was used to dissolve the purple formazan and the absorbance values at 490 nm were measured using a Synergy2 Microplate reader (BioTek Corporation). The representative images at 2 h were obtained under an inverted light microscope (Zeiss GmbH).

LX-2 cells (3×10⁵ cells/well) were seeded into a 6-well microplate until they formed a 90% confluent monolayer. The tip of a 200-µl sterile pipette was used to generate an artificial and uniform wound, and the unattached cells were carefully removed with 1X PBS. Cells were firstly treated with mitomycin at the concentration of 1 µg/ml at 37°C for 1 h in 5% CO₂ to inhibit cell division and then incubated in serum-free medium at 37°C for 12 h in 5% CO₂. The representative images at 0 and 12 h were captured under an inverted light microscope (Zeiss GmbH). The horizontal distance of the wound was calculated with ImageJ v1.8.0 (National Institutes of Health).

AutoDock Vina molecular docking software was used to simulate the combination of DHA and VEGFA proteins (http://autodock.scripps.edu/resources/raccoon) (18).

Blood was collected into clot activating tubes from rat orbital veins and was then centrifuged at 300 × g for 15 min at room temperature to collect the supernatant. An automatic biochemical analyzer (Hitachi, Ltd.) was used to detect the concentration of liver injury-related indicators alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), as well as the liver fibrosis-related indicators hyaluronic acid (HA), laminin (LN), type III procollagen (PC-III) and type IV collagen (IV-C) in rat serum.

The enrichment analysis of differentially expressed genes was conducted using bioinformatics analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG). The liver fibrosis-related miRNAs were analyzed using the following databases: GSE33857 (19), GSE49012 (20), GSE59492 (21), GSE74872 (22) from Gene Expression Omnibus (GEO) (http://www.ncbi.nih.gov/geo) (23), miRWalk (http://mirwalk.umm.uni-heidelberg.de/) (24), miR2Disease (http://www.mir2disease.org/) (25) and HMDD (http://www.cuilab.cn/hmdd) (26). The potential interactions between VEGFA and HSP60 protein were predicted using the following database: GeneMania (http://www.genemania.org/) (27). The target genes of miR-29b-3p were predicted using the following databases: miRWalk (http://mirwalk.umm.uni-heidelberg.de/), miRND (http://mirdb.org/) and TargetScan (https://www.targetscan.org/) (28). The thresholds in the GEO database were set as follows: P<0.05, fold change of all and gene rank of all. The KEGG enrichment analysis of differentially expressed genes between patients with different stages of liver fibrosis in the GSE33258 GEO dataset was performed using the ASSISTANT for Clinical Bioinformatics (https://www.aclbi.com/) (29). For KEGG analysis, P<0.05 or FDR <0.05 was considered to be a meaningful pathway [enrichment score with -log10(P) >1.3].

The present data are presented as the mean ± standard deviation. GraphPad Prism 7.0 was used to analyze the significance of the results (GraphPad Software, Inc.). Statistical significance was determined using an unpaired Student's t-test for comparisons between two groups, or one-way ANOVA followed by Tukey's post hoc test for comparisons among more than two groups. P<0.05 was considered to indicate a statistically significant difference. Each experiment was repeated at least three times.

Our previous study revealed that lncRNA H19 can prevent liver fibrosis in vivo and in vitro (30). The present study aimed to screen liver fibrosis-related miRNAs and explore their underlying mechanisms. Between normal and hepatic fibrosis samples, five significantly differentially expressed miRNAs were identified in four GEO datasets (GSE33857, GSE49012, GSE59492 and GSE74827), and two differentially expressed miRNAs were identified in three public databases (miRWalk, miR2Disease and HMDD) (Fig. 1A). Only miR-29b was revealed to be differentially expressed in all databases. Since miR-29b has two subtypes miR-29b-1 and miR-29b-2, and their 3p-ends are the same but their 5p-ends are different, miR-29b-3p was selected for further analysis (Fig. 1A).

The transfection efficacy of the miR-29b-3p mimic and miR-29b-3p inhibitor was confirmed by RT-qPCR (Fig. 1B). Notably, transfection with the miR-29b-3p mimic decreased the mRNA and protein expression levels of the fibrotic markers α-SMA and COL1A1 in LX-2 cells, whereas the inhibitor increased them (Figs. 1C, D and S1A). A previous study confirmed that COL1A1 and COL3A1 are targets of miR-29b-3p in mouse embryonic liver fibroblasts (31). In addition, the miR-29b-3p mimic decreased HSC viability, whereas the inhibitor increased it (Fig. 1E). Immunofluorescence staining results also revealed that the expression levels of α-SMA and COL1A1 were downregulated by the miR-29b-3p mimic but were upregulated by the inhibitor (Fig. 1F). Furthermore, ELISA analysis revealed that the miR-29b-3p mimic decreased the levels of IL-6, whereas the inhibitor increased these levels (Fig. 1G).

To explore the main mechanism of miR-29b-3p in liver fibrosis, KEGG analysis of differentially expressed genes between patients with early (I, II) and late (III, IV) liver fibrosis in the GSE33258 dataset were assessed (Fig. 2A). In addition, KEGG analysis of the target genes of hsa-miR-29b-3p was performed (Fig. S1B). 'VEGF signaling pathway' and 'fatty acid metabolism' were enriched in both. Moreover, 'Apoptosis-multiple species' and 'Autophagy-animal' were also involved.

The miR-29b-3p mimic restored the lipid droplet content in activated HSCs, as determined by oil red O and Nile red staining; however, the miR-29b-3p inhibitor had no apparent effect (Fig. 2B). The TG and TC assays also confirmed that the miR-29b-3p mimic significantly increased the levels of TG and TC, whereas the miR-29b-3p inhibitor decreased these levels (Fig. 2C). It has previously been reported that lipoprotein lipase (LPL) and HMGCR, as key enzymes in TG and cholesterol metabolism, are target genes of miR-29b-3p (32). The present study demonstrated that the mRNA and protein expression of LPL and HMGCR were inhibited by the miR-29b-3p mimic and activated by the miR-29b-3p inhibitor (Figs. 2D, E and S1C). Notably, the results revealed that the miR-29b-3p mimic increased TC levels and inhibited the expression levels of HMGCR, which is a rate-limiting enzyme of cholesterol synthesis.

Although lipid droplets were partially recovered in cells transfected with the miR-29b-3p mimic, trypan blue staining revealed that the miR-29b-3p mimic induced cell death (Fig. 3A). As shown in Figs. 2A and S1, the VEGF pathway may serve an important role in the development of liver fibrosis.

The VEGF family has four members: VEGFA, VEGFB, VEGFC and VEGFD. Except for VEGFC, the mRNA expression levels of other VEGF genes were inhibited by the miR-29b-3p mimic and activated by the miR-29b-3p inhibitor (Fig. 3B). VEGFA had the highest expression among them (33). In addition, VEGFA was predicted to be a target of miR-29b-3p through TargetScan, miRDB and miRWalk analyses (Fig. S2A). The miR-29b-3p mimic decreased the protein expression levels of VEGFA, whereas the miR-29b-3p inhibitor had the opposite effect (Figs. 3C and S2B). Immunofluorescence assays revealed that the miR-29b-3p mimic downregulated the expression levels of VEGFA, whereas the inhibitor upregulated them (Fig. 3D). Notably, VEGFA was confirmed as a direct target gene of miR-29b-3p via the luciferase assay (Fig. 3E).

The present study further verified the function of the miR-29b-3p/VEGFA axis. RT-qPCR confirmed successful transfection of the cells with the VEGFA siRNA (Fig. S2C). Compared with in the control group, VEGFA siRNA inhibited the protein expression levels of the fibrotic biomarkers COL1A1 and α-SMA, whereas the miR-29b-3p inhibitor increased the expression levels of these proteins. In addition, VEGFA siRNA increased the expression levels of Bax/Bcl-2 and LC3-II/LC3-I while decreasing p62, whereas the miR-29b-3p inhibitor had the opposite effects (Figs. 3F and S2D).

VEGFA has two main receptors: VEGFR1 and VEGFR2. RT-qPCR and western blot analysis demonstrated that VEGFR1 and VEGFR2 siRNAs were successfully transfected into LX-2 cells (Fig. S3A-C). Wound healing and adhesion assays demonstrated that VEGFR2 knockdown significantly inhibited the migratory and adhesive ability of LX-2 cells, whereas VEGFR1 knockdown had little effect (Fig. 4A and B). In addition, Annexin V-FITC/PI double staining and ELISA showed that VEGFR1 and VEGFR2 knockdown both induced the apoptosis and inhibited the inflammatory reaction via decreasing IL-6 expression of LX-2 cells (Fig. 4C and D).

Notably, western blot analysis was performed to detect the expression levels of autophagy-related proteins and it was revealed that VEGFR1 knockdown inhibited the expression levels of LC3-II/LC3-I and increased the expression levels of p62 in activated HSCs, whereas VEGFR2 knockdown increased the expression levels of LC3-II/LC3-I and inhibited the expression levels of p62 in activated HSCs (Figs. 4E and S3D). LX-2 cells were further treated with the VEGFR1-specific inhibitor GNQWFI and the VEGFR2-specific inhibitor SU5416 at concentrations of 0.02, 0.2, 2 and 10 µM (Fig. S3E). The results revealed that 2 µM GNQWFI and 0.2 µM SU5416 significantly inhibited the expression levels of VEGFR1 and VEGFR2, respectively (Fig. S3C). Western blot analysis demonstrated that the autophagy-related protein LC3-II/LC3-I was decreased after GNQWFI treatment but increased after SU5416 treatment (Figs. 4F and S3F). In addition, both knockdown of VEGFR1 and VEGFR2 increased the expression levels of Bax/Bcl-2 (Figs. 4E, F and S3D).

Numerous studies have reported that the PI3K/AKT pathway is the main downstream signal of VEGFR2 and is essential in inducing autophagy (17,34,35). Western blot analysis revealed that VEGFR2 siRNA significantly reduced the phosphorylation levels of PI3K and AKT, and these changes were reversed by the PI3K-specific agonist 740Y-P (Figs. 5A and S4A). Western blot analysis also revealed that VEGFR2 knockdown inhibited the phosphorylation of mTOR and ULK1, whereas 740Y-P had the opposite effect (Fig. 5A).

In addition to inducing autophagy, VEGFR2 knockdown simultaneously promoted cell apoptosis (Fig. 4C). Analysis using GeneMania, a protein interaction prediction website, revealed a potential interaction between VEGFR2 and the mitochondrial stabilizing protein HSP60 (Fig. S4B). A fluorescence colocalization assay revealed that VEGFR2 and HSP60 were colocalized in the LX-2 cytoplasm under normal conditions, and the colocalization level was markedly weakened after transfection with VEGFR2 siRNA (Fig. 5B). Immunoprecipitation assays showed that the VEGFR2 protein could bind to the HSP60 protein (Fig. 5C). RT-qPCR and western blot analysis revealed that the CMV-14-HSP60 plasmid was successfully transfected into LX-2 cells (Figs. S4C, 4D and 5D). Western blot analysis also revealed that the expression levels of AIF, cytochrome c and cleaved caspase-9/pro-caspase-9 were markedly increased after VEGFR2 knockdown; these effects were reversed by HSP60 overexpression (Figs. 5D and S4D). VEGFR2 knockdown also induced an imbalance in mitochondrial membrane potential, but HSP60 overexpression reversed this imbalance (Fig. 5E).

The present results revealed that VEGFR2 knockdown decreased the protein expression levels of HSP60, whereas the miR-29b-3p inhibitor reversed this condition (Fig. 5F). Immunoprecipitation assays showed that the ubiquitination of HSP60 increased after VEGFR2 knockdown, and miR-29b-3p intervention partly reduced this increase (Figs. 5F and S4E). These findings indicated that VEGFR2 may inhibit apoptosis by binding with HSP60 to prevent its ubiquitination and degradation, and mitochondrial homeostasis (36,37).

A previous study screened the small molecule agonist DHA from natural products and revealed that it could prevent fibrosis; therefore, the present study aimed to confirm the relationship between miR-29b-3p and DHA in fibrosis treatment (30).

The CCK-8 assay showed that DHA decreased the viability of LX-2 cells in a dose-dependent manner (Fig. 6A). Furthermore, miR-29b-3p expression was significantly higher in HSCs treated with DHA compared with that in the control group (Fig. 6B). The mRNA and protein expression levels of LPL and VEGFA in HSCs were significantly decreased following treatment with DHA in a dose-dependent manner (Figs. 6C, D and S5A). DHA also increased intracellular TG and TC levels (Fig. 6E), and inhibited HSP60 protein expression (Fig. 6D) in a dose-dependent manner.

Furthermore, DHA treatment enhanced the protein expression levels of Bax/Bcl-2, LC3-II/LC3-I and cleaved caspase-9/pro-caspase-9, and decreased the expression levels of p62, VEGFA, α-SMA and COL1A1 in LX-2 cells, whereas miR-29b-3p inhibition reversed these effects (Figs. 6F and S5B). In addition, molecular docking indicated a strong direct interaction of DHA with VEGFA protein (docking score, -5.9 kcal/mol), thus indicating that DHA not only regulated VEGFA mRNA via miR-29b-3p but also by directly acting on the VEGFA protein (Fig. 6G).

To further confirm the specific mechanism underlying the effects of DHA treatment on liver fibrosis, a rat model of liver fibrosis was established via intraperitoneal injection of CCl₄. An AAV8 miR-29b-3p mimic was used to increase miR-29b-3p expression via caudal vein injection. RT-qPCR confirmed the successful intervention of AAV8 miR-29b-3p mimic in the liver of rats (Fig. S5C). Liver morphology evaluations confirmed the successful construction of the liver fibrosis model, which exhibited obvious fibrotic lesions compared with in the control group. Treatment with the miR-29b-3p mimic and DHA markedly reduced fibrotic lesions in the liver (Fig. 7A). In addition, H&E staining was used to investigate the effects of the AAV8 miR-29b-3p mimic and DHA on hepatic injury and inflammation. Intraperitoneal injection of CCl₄ induced inflammatory infiltration, hepatic fibrous septum formation and hepatocyte disorder; however, these effects were attenuated by the AAV8 miR-29b-3p mimic and DHA. The results of Masson and Sirius Red staining also revealed that large amounts of collagen and matrix were deposited around the hepatic fibrous scar area in the model group, but were effectively reduced by the AAV8 miR-29b-3p mimic and DHA (Fig. 7A). Serological examination demonstrated that hepatic injury biomarkers (ALT, AST, ALP, HA111, LN, PC-III and IV-C) were higher in the model group than in the AAV8 miR-29b-3p mimic and DHA treatment groups, which is consistent with our previous conclusion that miR-29b-3p and DHA inhibited HSC activity and reversed activated HSCs into a static condition (Fig. 7B).

The mRNA and protein expression levels of α-SMA and COL1A1 were significantly upregulated in the model group, whereas they were downregulated by the AAV8 miR-29b-3p mimic and DHA (Figs. 7C, D and S5D). Immunofluorescence double staining revealed that the expression of VEGFA and HSP60 in fibrotic tissue was inhibited by the AAV8 miR-29b-3p mimic or DHA, whereas LC3B expression was increased. Fibrotic liver tissue was stained with α-SMA (Fig. 7E).